Immune-stimulating monoclonal antibodies against human interleukin-2
AssigneeUniversitäT ZüRich
InventorsOnur Boyman, Natalia Arenas-Ramirez, Chao Zou
Life of this patent
Estimating the term…
Abstract
The invention relates to a human lnterieuldn-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hlL-2 inhibits binding of hlL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)≤7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)≤1×10−4 s−1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.
Claims25
1-19. (canceled)
A fusion protein comprising:
- a) a VH domain fragment, wherein said VH domain fragment comprises amino acid sequences of SEQ ID NOs:
- 007, 008 and 009;
- b) a VL domain fragment, wherein said VL domain fragment comprises amino acid sequences SEQ ID NOs:
- 010, 011, and 012;
- and
- c) a human interleukin 2 (hIL-2) polypeptide comprising an amino acid sequence having at least 80% sequence identify to SEQ ID NO:001 or SEQ ID NO:002, wherein said hIL-2 polypeptide has hIL-2 activity.
Dependencies are inferred from the claim text.